The Use of ARA290 for the Treatment of Diabetic Macular Oedema

Summary

ARA 290-DMO is a prospective, open label, interventional, single centre, investigator led, phase II trial to examine the effect of ARA 290 on diabetic macular oedema in patients with type 1 or 2 diabetes. The aim or primary objective of the study was to determine whether ARA 290 administered at a daily dose of 4mg subcutaneously for 12 weeks to patients with diabetes mellitus (DM) and DMO would have a beneficial effect on mean change in best corrected visual acuity (BCVA) from baseline values to week 12.

Timeline

Start

2016-04

Primary completion

2017-05-12

Completion

2017-08

Outcome

Outcome not reported

Stopped: “Expiry of study drug - no replacement available.”

Drugs

Indications